Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2017

Nguyen DP, O'Malley P, Awamlh BA, Furrer M-, Mongan NP, Robinson BD, et al. Association of Aromatase With Bladder Cancer Stage and Long-Term Survival: New Insights Into the Hormonal Paradigm in Bladder Cancer. Clin Genitourin Cancer. 2017;15(2):256-262.e1.

Jessurun J. The Differential Diagnosis of Acute Colitis: Clues to a Specific Diagnosis. Surg Pathol Clin. 2017;10(4):863-885.

Nwanze J, Siddiqui MT, Stevens KA, Saxe D, Cohen C. MYC Immunohistochemistry Predicts Rearrangements by FISH. Front Oncol. 2017;7:209.

McHugh D, Caduff N, Barros MH, Rämer PC, Raykova A, Murer A, et al. Persistent KSHV Infection Increases EBV-Associated Tumor Formation In Vivo via Enhanced EBV Lytic Gene Expression. Cell Host Microbe. 2017;22(1):61-73.e7.

Liu C, Zhao Z, Fan J, Lyon CJ, Wu H-, Nedelkov D, et al. Quantification of circulating antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc Natl Acad Sci U S A. 2017;114(15):3969-3974.

Dinerman BF, Khani F, Golan R, Bernstein AN, Cosiano MF, Margolis DJ, et al. Population-based study of the incidence and survival for intraductal carcinoma of the prostate. Urol Oncol. 2017;35(12):673.e9-673.e14.

Sangoi AR, Kshirsagar M, Roma AA, Horvai AE, Chivukula M, Ellenson LH, et al. Interobserver Reproducibility Among Gynecologic Pathologists in Diagnosing Heterologous Osteosarcomatous Component in Gynecologic Tract Carcinosarcomas. Int J Gynecol Pathol. 2017;36(4):386-392.

Chadburn A, Said J, Gratzinger D, Chan JK, de Jong D, Jaffe ES, et al. HHV8/KSHV-Positive Lymphoproliferative Disorders and the Spectrum of Plasmablastic and Plasma Cell Neoplasms: 2015 SH/EAHP Workshop Report-Part 3. Am J Clin Pathol. 2017;147(2):171-187.

Halteh P, Huang J, Wildman HF, Magro CM. Gadolinium-Naive Nephrogenic Systemic Fibrosis of Breast Mimicking Inflammatory Breast Carcinoma. Am J Dermatopathol. 2017;39(4):322-324.

Calvert AE, Chalastanis A, Wu Y, Hurley LA, Kouri FM, Bi Y, et al. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation. Cell Rep. 2017;19(9):1858-1873.